Hudson Bay Capital Management’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.7M Buy
356,535
+116,535
+49% +$2.52M 0.03% 372
2025
Q4
$5.72M Sell
240,000
-100,000
-29% -$2.04M 0.02% 471
2025
Q3
$4.62M Sell
340,000
-90,000
-21% -$936K 0.02% 568
2025
Q2
$3.5M Buy
430,000
+61,450
+17% +$525K 0.01% 648
2025
Q1
$2.89M Buy
368,550
+198,550
+117% +$2.3M 0.01% 744
2024
Q4
$2.53M Sell
170,000
-5,000
-3% -$81.7K 0.01% 614
2024
Q3
$2.68M Buy
175,000
+15,000
+9% +$237K 0.01% 530
2024
Q2
$2.44M Sell
160,000
-5,000
-3% -$80.7K 0.01% 503
2024
Q1
$3.12M Sell
165,000
-5,000
-3% -$86.5K 0.02% 395
2023
Q4
$3.25M Buy
170,000
+90,000
+113% +$1.44M 0.02% 372
2023
Q3
$1.44M Sell
80,000
-35,000
-30% -$703K 0.01% 521
2023
Q2
$2.34M Buy
115,000
+200
+0.2% +$3.81K 0.02% 483
2023
Q1
$2.09M Buy
114,800
+64,800
+130% +$1.24M 0.02% 514
2022
Q4
$1.03M Buy
50,000
+25,000
+100% +$688K 0.01% 679
2022
Q3
$654K Sell
25,000
-6,000
-19% -$159K 0.01% 877
2022
Q2
$786K Buy
31,000
+21,000
+210% +$514K 0.01% 958
2022
Q1
$316K Buy
+10,000
New +$335K ﹤0.01% 895
2020
Q4
Sell
-85,000
Closed -$1.46M 686
2020
Q3
$1.46M Sell
85,000
-25,000
-23% -$559K 0.02% 389
2020
Q2
$2.72M Buy
+110,000
New +$2.97M 0.05% 275

Other funds holding RCUS

Hudson Bay Capital Management's RCUS Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Arcus Biosciences (RCUS) stake by 49% in Q1 2026, buying an estimated $2.52M and bringing the position to 356,535 shares worth $7.7M. The position accounts for 0.03% of the portfolio, ranked #372.

Hudson Bay Capital Management first reported a position in RCUS in Q2 2020 and has held it in 19 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Hudson Bay Capital Management held 356,535 shares of Arcus Biosciences worth $7.7M as of Q1 2026.
  • Hudson Bay Capital Management bought 116,535 Arcus Biosciences shares in Q1 2026, an estimated $2.52M.
  • Arcus Biosciences made up 0.03% of Hudson Bay Capital Management's portfolio in Q1 2026, its #372 holding.
  • Hudson Bay Capital Management first reported a position in Arcus Biosciences in Q2 2020 and has held it in 19 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.